Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates

International Journal of Infectious Diseases

Volumn 26, Issue , 2014, Pages 149-153

  Ho, Jennifer ^a,b   Jelfs, Peter ^a   Sintchenko, Vitali ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Prevalence; Second line drug resistance; Susceptibility testing

Indexed keywords

CIPROFLOXACIN; ISONIAZID; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; DNA SEQUENCE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NON MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; FEMALE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; FEMALE; FLUOROQUINOLONES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NEW SOUTH WALES; PROSPECTIVE STUDIES; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84907310600     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.03.1388     Document Type: Article

References (53)

1. Nuermberger E.L., Yoshimatsu T., Tyagi S., O'Brien R.J., Vernon A.N., Chaisson R.E., et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004, 169:421-426.
2. Cremades R., Rodriguez J.C., Garcia-Pachon E., Galiana A., Ruiz-Garcia M., Lopez P., Royo G., et al. Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. J Antimicrob Chemother 2011, 66:2281-2283.
3. World Health Organization. Treatment of tuberculosis guidelines. 4th ed. Geneva: WHO; 2010. Available at: (accessed January 25, 2014). http://www.who.int/tb/publications/tb_treatmentguidelines/en/index.html.
4. Blumberg H.M., Burman W.J., Chaisson R.E., Daley C.L., Etkind S.C., Friedman L.N., et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167:603-662.
5. Wang J.Y., Wang J.T., Tsai T.H., Hsu C.L., Yu C.J., Hsueh P.R., et al. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010, 14:65-71.
6. Conde M.B., Efron A., Loredo C., De Souza G.R., Graca N.P., Cezar M.C., et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 373:1183-1189.
7. World Health Organization. Global tuberculosis report 2013. Geneva: WHO; 2013. Available at: (accessed January 25, 2014). http://www.who.int/tb/publications/global_report/en/.
8. Yew W.W., Chan C.K., Chau C.H., Tam C.M., Leung C.C., Wong P.C., Lee J. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000, 117:744-751.
9. Kim D.H., Kim H.J., Park S.K., Kong S.J., Kim Y.S., Kim T.H., et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010, 182:113-119.
10. Huang T.S., Kunin C.M., Shin-Jung Lee S., Chen Y.S., Tu H.Z., Liu Y.C. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005, 56:1058-1062.
11. Park I.N., Hong S.B., Oh Y.M., Lim C.M., Lee S.D., Lew W.J., et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007, 11:319-324.
12. Migliori G.B., Langendam M.W., D'Ambrosio L., Centis R., Blasi F., Huitric E., et al. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones. Eur Respir J 2012, 40:814-822.
13. Ginsburg A.S., Hooper N., Parrish N., Dooley K.E., Dorman S.E., Booth J., et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003, 37:1448-1452.
14. Devasia R.A., Blackman A., Gebretsadik T., Griffin M., Shintani A., May C., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009, 180:365-370.
15. Agrawal D., Udwadia Z.F., Rodriguez C., Mehta A. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai. India. Int J Tuberc Lung Dis 2009, 13:79-83.
16. Grimaldo E.R., Tupasi T.E., Rivera A.B., Quelapio M.I., Cardano R.C., Derilo J.O., Belen V.A. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001, 5:546-550.
17. National Notifiable Diseases Surveillance System. Australia's notifiable disease status, 2011: Annual report of the National Notifiable Diseases Surveillance System. Australia: NNDSS; 2011. Available at: (accessed January 25, 2014). http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-2011-annual-report.htm.
18. Lumb R., Bastian I., Carter R., Jelfs P., Keehner T., Sievers A. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2010. A report of the Australian Mycobacterium Reference Laboratory Network. Commun Dis Intell Q Rep 2013, 37:E40-E46.
19. Barry C., Waring J., Stapledon R., Konstantinos A. Tuberculosis notifications in Australia, 2008 and 2009. Commun Dis Intell 2012, 36:82-94.
20. Australian Bureau of Statistics. Australia: 2013. Migration, Australia, 2011-12 and 2012-13. State and territory composition of country of birth; Available at: (accessed January 25, 2014). http://www.abs.gov.au/ausstats/absat.nsf/Lookup/BEF8BD30A177EC39CA257C4400238EED%3Fopendocument.
21. Feng Y., Liu S., Wang Q., Wang L., Tang S., Wang J., Lu W. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLoS one 2013, 8:e55292.
22. Chang K.C., Yew W.W., Chan R.C. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2010, 65:1551-1561.
23. Palomino J.C., Traore H., Fissette K., Portaels F. Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1999, 3:344-348.
24. Huang W.L., Chi T.L., Wu M.H., Jou R. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2011, 49:2502-2508.
25. Hall L., Jude K.P., Clark S.L., Dionne K., Merson R., Boyer A., et al. Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and second-line agents. J Clin Microbiol 2012, 50:3732-3734.
26. Lau R.W., Ho P.L., Kao R.Y., Yew W.W., Lau T.C., Cheng V.C., et al. Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. Antimicrob Agents Chemother 2011, 55:608-614.
27. Lai C.C., Tan C.K., Huang Y.T., Liao C.H., Hsueh P.R. Fluoroquinolone-resistant tuberculosis at a medical centre in Taiwan, 2005-10. J Antimicrob Chemother 2011, 66:2437-2438.
28. Tessema B., Beer J., Emmrich F., Sack U., Rodloff A.C. First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia. Int J Tuberc Lung Dis 2012, 16:805-811.
29. van den Boogaard J., Semvua H.H., van Ingen J., Mwaigwisya S., van der Laan T., van Soolingen D., et al. Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania. J Antimicrob Chemother 2011, 66:1810-1814.
30. Umubyeyi A.N., Rigouts L., Shamputa I.C., Fissette K., Elkrim Y., de Rijk P.W., et al. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother 2007, 59:1031-1033.
31. Rafiq Y., Jabeen K., Hasan R., Jafri S., Laiq R., Malik F., et al. Fluoroquinolone resistance among Mycobacterium tuberculosis strains from Karachi, Pakistan: data from community-based field clinics. Antimicrob Agents Chemother 2011, 55:929-930.
32. Casal M., Ruiz P., Herreras A. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance. Int J Tuberc Lung Dis 2000, 4:588-591.
33. El Sahly H.M., Teeter L.D., Jost K.C., Dunbar D., Lew J., Graviss E.A. Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas. J Clin Microbiol 2011, 49:2942-2945.
34. Bozeman L., Burman W., Metchock B., Welch L., Weiner M. Tuberculosis Trials C Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005, 40:386-391.
35. Verma J.S., Nair D., Rawat D., Manzoor N. Assessment of trends of ofloxacin resistance in Mycobacterium tuberculosis. Indian J Med Microbiol 2011, 29:280-282.
36. Xu P., Li X., Zhao M., Gui X., DeRiemer K., Gagneux S., et al. Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother 2009, 53:3170-3172.
37. Singh M., Chauhan D.S., Gupta P., Das R., Srivastava R.K., Upadhyay P., et al. In vitro effect of fluoroquinolones against Mycobacterium tuberculosis isolates from Agra and Kanpur region of North India. Indian J Med Res 2009, 129:542-547.
38. Soudani A., Hadjfredj S., Zribi M., Messaoud T., Masmoudi A., Majed B., Fendri C. First report of molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates from a Tunisian hospital. Clin Microbiol Infect 2010, 16:1454-1457.
39. Pardini M., Iona E., Varaine F., Karakozian H., Arzumanian H., Brunori L., et al. Mycobacterium tuberculosis drug resistance. Abkhazia. Emerg Infect Dis 2005, 11:501-503.
40. Wang J.Y., Lee L.N., Lai H.C., Wang S.K., Jan I.S., Yu C.J., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007, 59:860-865.
41. Cheng A.C., Turnidge J., Collignon P., Looke D., Barton M., Gottlieb T. Control of fluoroquinolone resistance through successful regulation, Australia. Emerg Infect Dis 2012, 18:1453-1460.
42. Therapeutic guidelines: Antibiotic. Version 14. Melbourne: Therapeutic Guidelines Limited; 2010.
43. Gram Negative Survey: 2008 antimicrobial susceptibility report. Adelaide, Australia: Australian Group on Antimicrobial Resistance; 2011.
44. Lowbridge C., Christensen A., McAnulty J.M. EpiReview: tuberculosis in NSW, 2009-2011. N S W Public Health Bull 2013, 24:3-9.
45. Long R., Chong H., Hoeppner V., Shanmuganathan H., Kowalewska-Grochowska K., Shandro C., et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009, 48:1354-1360.
46. Grossman R.F., Hsueh P.R., Gillespie S.H., Blasi F. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones. Int J Infect Dis 2014, 18:14-21.
47. Shen G.H., Tsao T.C., Kao S.J., Lee J.J., Chen Y.H., Hsieh W.C., et al. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis?. Controversies and solutions. Int J Antimicrob Agents 2012, 39:201-205.
48. Chen T.C., Lu P.L., Lin C.Y., Lin W.R., Chen Y.H. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 2011, 15:e211-e216.
49. Durham L.K., Ge M., Cuccia A.J., Quinn J.P. Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli. Eur J Clin Microbiol Infect Dis 2010, 29:353-356.
50. Sanchez G.V., Master R.N., Karlowsky J.A., Bordon J.M. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012, 56:2181-2183.
51. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth global report. Geneva: WHO; 2008.
52. Ginsburg A., Grosset J., Bishai W. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003, 3:432-442.
53. Moadebi S., Harder C.K., Fitzgerald M.J., Elwood K.R., Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007, 67:2077-2099.